On October 26, 2026, HIMS closed at $27.59, down 0.43% from the prior close and underperforming a positive tape as the S&P 500 rose 0.70% and the Nasdaq gained 0.82%; volume was only 5.73 million shares, 0.58x the 20-day average. The macro backdrop is Neutral rather than favorable: eased to 18.39, but the 10-year Treasury yield remains elevated at 4.986%, leaving little valuation cushion for a 2.43-beta, unprofitable growth stock. The fundamental bull case still rests on real scale—38.2% year-over-year revenue growth, 2.89 million customers, and a 69.53% gross margin—but operating margin is -12.75%, margin is -0.40%, is -32.03%, and net debt is about $705 million. Valuation remains demanding: the supplied forward is 37.4x, is 2.53, is 2.50x versus a cited healthcare average of 1.3x, and is not meaningful because is negative. Estimate momentum is clearly negative; FY26 consensus has fallen to -$0.56027 from -$0.13 ninety days ago and FY27 is down about 32% to $0.41908, while the last two reported quarters missed estimates by $0.32 and $0.43. Technically, price is roughly 5.0%-5.7% below the 20-day , 50-day , and 200-day , the 50-day remains below the 200-day , histogram is widening negative at -0.1475, is 43.79, and continues to slip. The September 26 AI-native weight-loss platform launch is a credible strategic positive, but unresolved privacy and billing litigation plus a referenced FTC lawsuit keep the news tone mixed-bearish. Earnings on November 9 are only 13 days away, making the near-term setup event-driven after two consecutive large misses; the $31.15 mean target implies about 12.9% upside, but the $23 low target implies about 16.6% downside and short interest is 28.22% of float. We maintain HOLD overall, with a SELL near-term posture and HOLD views over six and twelve months.
Decision
Live price
$28.16
Recommendation score
42%
42%
Confidence
65%
65%
Outlook by horizon
1M
SELL
Near
6M
HOLD
Mid
1Y
HOLD
Long
Primary catalyst
The November 9 earnings report is the most likely near-term market mover: consensus expects to return to +$0.05632 after two consecutive large misses, while current operating margins and sharply reduced fiscal estimates leave little evidence of an established recovery. is about 6.35% of price and short interest is 28.22% of float, making a move greater than 5% plausible; an adverse privacy, billing, or regulatory headline could also cause an unscheduled gap.
Stability ClassHigh-Beta GrowthPortfolio RoleSatellite UpsideDrawdown RiskVery HighRisk ProfileSpeculativeConsumer TelehealthAI-Enabled Weight-Loss CareNegative EPS RevisionsEarnings Event RiskPrivacy and Billing ScrutinyVery High Volatility
Decision Workspace
Price Map
60-day setup
Price rail
$28.16
Stop
Now
$24
$27
$29
$32
Stop loss
$24.70
Entry
$26.35 - $27.20
Exit
$29.05 - $31.15
Risk / reward
1.6x
Watch size
Downside to stop
-12.3%
Upside to exit
+10.6%
Position sizing
Avoid opening a fresh long position before the November 9 report. Any existing exposure should remain a small satellite allocation, no more than roughly 0.5%-1.0% of portfolio value, and must be sized to withstand a 10% or larger event move; is about 6.35% of price, realized 20-day volatility is 61.65%, and short interest is 28.22% of float. Do not average down solely because price has returned near the prior $27-$28 entry band.
Thesis Snapshot
Why It Works
The strongest case for owning HIMS is that a real, growing consumer platform already has 2.89 million customers, 38.2% revenue growth, and 69.53% gross margin, leaving meaningful operating leverage if customer acquisition, cross-selling, and the AI-native weight-loss program translate into better retention and lower service costs. The shares are 45.03% below their 52-week high, the $31.15 analyst mean target is about 12.9% above the current $27.59 close, and short interest of 28.22% of float could amplify a credible earnings recovery. The prior $26.35-$27.50 entry band was effectively retested, with the October 26 low at $27.22 and close at $27.59, while the prior $24.70 stop has not been reached. However, the prior $29.05-$31.15 exit zone remains unreached and the current price is about 5.0% below its lower edge; that history argues for waiting for confirmation rather than treating a retest as proof of a durable reversal.
What Breaks It
The strongest argument against the HOLD rating is that HIMS may be a fast-growing but structurally low-return business whose weight-loss and subscription growth cannot overcome customer-acquisition, care-delivery, and regulatory costs: operating margin is -12.75%, margin is -0.40%, is -32.03%, and the two latest supplied quarters missed by about $0.32 and $0.43 per share. FY26 consensus worsened from -$0.13 to -$0.56027 in 90 days and FY27 fell 32% to $0.41908, while the current quarter is still expected to return to positive . The October 26 close of $27.59 slipped below the October 23 close and left price 5.0%-5.7% below its principal moving averages as and weakened. At $27.59, the analyst mean implies about 12.9% upside but the low target implies 16.6% downside, and the 37.4x forward , 2.53 , and 2.50 price-to-sales multiple offer little comfort if estimates keep falling. The short thesis is that regulatory or privacy scrutiny damages trust and subscription economics while operating losses and net debt persist; short interest is 28.22% of float with a 5.76 short ratio, but the bundle contains no time series to determine whether bearish positioning is rising or being covered.
A daily close below the October 15 structural low of $26.33 invalidates the recent base and the tactical stabilization thesis; exit rather than interpreting that break as routine volatility.
Earnings and revision risk: the latest supplied quarter missed by $0.32 per share and the prior quarter by about $0.43; FY26 consensus fell from -$0.13 to -$0.56027 and FY27 declined about 32% to $0.41908, with the November 9 report only 13 days away.
Profitability, leverage, and cash-conversion risk: operating margin is -12.75%, margin is -0.40%, debt-to-equity is 477.13%, net debt is about $705 million, and the reported $849 million of free cash flow is about 3.2x operating cash flow of $263 million.
Regulatory and legal risk: supplied coverage reports privacy and billing litigation and regulatory complaints and references an FTC lawsuit; no outcome, quantified liability, or resolution timeline is available.
Valuation and multiple-compression risk: is 2.53, price-to-sales is 2.50x versus cited healthcare and peer averages of 1.3x and 2.2x, and the reported 37.4x forward is difficult to reconcile with negative FY26 and modest FY27 consensus .
Volatility and positioning risk: beta is 2.43, realized 20-day volatility is 61.65%, is about 6.35% of price, and short interest is 28.22% of float; no short-interest history is supplied, so a rising or falling trend in bearish conviction cannot be confirmed.
Watch Next
Next earnings: Nov 9, 2026
The November 9 earnings report is the most likely near-term market mover: consensus expects to return to +$0.05632 after two consecutive large misses, while current operating margins and sharply reduced fiscal estimates leave little evidence of an established recovery. is about 6.35% of price and short interest is 28.22% of float, making a move greater than 5% plausible; an adverse privacy, billing, or regulatory headline could also cause an unscheduled gap.
Signal Dashboard
Decision inputs
6 signals
Fundamental
12.9%
Upside to analyst mean target
Trailing is unavailable because HIMS is loss-making. The supplied forward is 37.4x and is 2.53, above the 1.5x threshold generally considered attractive for a growth company, while FY26 consensus is -$0.56027 and FY27 is only $0.41908, making the forward multiple sensitive to any estimate cut. At $27.59, the stock is about 65.8x the FY27 consensus , underscoring how much of the valuation depends on a sharp profit inflection rather than current earnings. of -704.56x is not meaningful with negative ; of 2.50x is about 92% above the cited 1.3x healthcare average and about 14% above the 2.2x peer average, and is 19.86x. Enterprise value of approximately $7.17 billion is 1.11x the $6.44 billion market cap, reflecting the net-debt position. A third-party Fair Ratio model cited in coverage argues for a higher tailored sales multiple, but that is assumption-dependent and does not establish that current profitability or cash conversion supports a premium. Overall, the stock is expensive relative to its current earnings quality and balance-sheet risk, even though revenue growth is strong.
Technical
Bearish
Trend quality
At the October 26 close of $27.59, price was about 5.0% below the 20-day of $29.05, 5.4% below the 50-day of $29.17, and 5.7% below the 200-day of $29.24. The 50-day is about 0.24% below the 200-day , a marginal death-cross configuration that developed in mid-October rather than a deeply established long-term trend break. The October 26 session made a lower low at $27.22, below the October 23 low of $27.30, but closed at $27.59, still above the October 15 structural low of $26.33; the near-term trend is bearish while the broader recent base is not yet fully broken.
Earnings
13d
Deteriorating
The latest supplied quarter, ended June 30, 2026, reported of -$0.37 versus -$0.05 estimated, a $0.32 miss, following March-quarter of -$0.40 versus +$0.02557 estimated; no market reaction or company guidance detail is supplied, and consensus expects +$0.05632 for the next quarter due November 9.
News
Mixed-Bearish
Headline tone
The November 9 earnings report is the most likely near-term market mover: consensus expects to return to +$0.05632 after two consecutive large misses, while current operating margins and sharply reduced fiscal estimates leave little evidence of an established recovery. is about 6.35% of price and short interest is 28.22% of float, making a move greater than 5% plausible; an adverse privacy, billing, or regulatory headline could also cause an unscheduled gap.
Macro
Neutral
4.99% 10Y / 18.4 VIX
at 18.39 is still in the Neutral band and the 10-year yield at 4.986% remains high, so a 2.43-beta, unprofitable growth stock gets little valuation relief and remains exposed to multiple compression if yields back up.
Stability
High-Beta Growth
Satellite Upside
HIMS has a scaled consumer telehealth platform, 38.2% year-over-year revenue growth, 2.89 million customers, and a 69.53% gross margin, so the business is not a pre-revenue binary proposition. However, a -12.75% operating margin, -0.40% margin, -32.03% , and approximately $705 million of net debt show that durable earnings power and balance-sheet flexibility remain unproven. of 2.43, realized 20-day volatility of 61.65%, of about 6.35% of the current share price, and short interest at 28.22% of float imply severe day-to-day and event-driven drawdown risk. It belongs in a small satellite-growth allocation rather than a core holding, with position size set to withstand a sharp earnings or regulatory gap.
Analyst Spread
Mean Target
$31.15
High / Low
$23 / $42
Median Target
$31.00
Consensus range
$23 - $42
— analysts
Mean
$23$31$42
Consensus
At $27.59, the $31.15 mean target implies approximately 12.9% upside and the $31.00 median target implies approximately 12.4%; the $23 low target implies about 16.6% downside, while the $42 high implies about 52.2% upside. The wide target range signals material disagreement about profitability, regulatory exposure, and the durability of weight-loss-related growth. The analyst-count field is null, so coverage breadth cannot be verified; the recommendation snapshot shows 15 ratings, with 12 Holds and only 3 Buy or Strong Buy opinions. Truist, BofA, and Deutsche Bank raised price targets in August, while Barclays and Citigroup lowered theirs, without reported rating-grade changes.
Positioning Pulse
Insider Signal
Neutral
Net Bias
No recent activity
Insider Own.
4.9%
Institutional Own.
71.2%
Interpretation
The supplied insider records are too incomplete and internally inconsistent to infer management confidence or to distinguish automatic sales from discretionary activity.
Notable activity
Two ambiguous Form-4 rows list Officer Michael Y. Chi with 26,600 direct-ownership shares each, but transaction types are blank and the date fields are coded as 149 and 148. The reported values imply prices of roughly $66.98 and $7.13 per share for identical share counts, so the entries cannot be reliably classified as open-market purchases, discretionary sales, option exercises, or 10b5-1 transactions.
Market Context
Industry
Drug Manufacturers - Specialty & Generic
Mixed-Bearish
Sentiment
-28
Tracked names
1
Grouping
industry
Drug Manufacturers - Specialty & Generic industry is currently Mixed-Bearish with an average recommendation score near 42. capital and conviction are fading across the group, and leadership is still concentrated.
Rotation Drivers
Average recommendation deltas are rolling over across Drug Manufacturers - Specialty & Generic industry, which points to capital rotating away from the group.
0 names are rated bullish versus 0 bearish names, keeping the group tone mixed-bearish.
Leaders To Watch
Related leaders
No other tracked leaders yet.
Themes
AI-Enabled Weight-Loss Care
Score: 10
Mixed-Bullish
The September 26 AI-native platform launch places HIMS in a personalized, digitally delivered weight-loss care narrative, and 38.2% revenue growth with 2.89 million customers provides evidence of underlying demand. However, the company has not quantified incremental platform revenue, retention, or margin contribution, and the October 26 close of $27.59 remains 45.0% below the 52-week high despite the launch. The bundle contains no peer-return or fund-flow data, so active capital rotation into this theme cannot be established.
The November 9 earnings report is the first near-term test of whether the new platform can support engagement and growth without worsening already negative operating margins.
The September 26 launch reinforces the personalized, recurring-care narrative, but no reported financial contribution is available yet.
HIMS fell 0.43% on October 26 while the Nasdaq rose 0.82%, showing stock-specific weakness rather than evidence of current rotation into HIMS.
Digital Health Regulatory and Privacy Scrutiny
Score: -35
Bearish
Supplied September coverage reports a class action and regulatory complaints concerning privacy and billing, and references an FTC lawsuit; these allegations remain unresolved in the bundle. Regulatory or trust-related pressure could weigh directly on a subscription-based care-delivery intermediary even if demand for weight-loss treatments remains strong. No refreshed peer prices, market capitalizations, relative returns, or flow data are supplied to confirm an active rotation away from the group, so this remains a risk narrative rather than a measured capital-flow signal.
The legal and regulatory reports are unresolved and the November 9 earnings report is imminent, leaving the stock exposed to both headline risk and scrutiny of category economics.
The reported privacy, billing, and regulatory concerns touch the company's consumer subscription and care-delivery model, but no quantified legal exposure or resolution is provided.
HIMS is 45.03% below its 52-week high, but without current peer performance or fund-flow evidence the data do not establish where sector capital is rotating.
Key Stats
23 metrics total
Market Cap
$6.44B
P/E (TTM)
0.0
Forward P/E
37.4
Revenue Growth
38.2%
ROE
-32.0%
Beta
2.43
Full Metric Set
17 additional stats
Valuation Stack
Multiples and cash-flow framing.
Price / Sales
2.5
Price / Book
19.9
EV / EBITDA
-704.6
Quality & Balance Sheet
Margins, leverage, and liquidity.
Gross Margin
69.5%
Operating Margin
-12.8%
Debt / Equity
477.1
Current Ratio
0.93x
Quick Ratio
0.82x
Positioning & Range
Short interest and 52-week location.
Short % Float
28.2%
Short Ratio
5.76x
52W High
$50.19
52W Low
$13.74
From 52W High
-45.0%
From 52W Low
100.8%
Company Classification
Sector and industry context.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Additional Signals
Free Cash Flow
$849437248.00
Detailed Analysis
Valuation
Trailing is unavailable because HIMS is loss-making. The supplied forward is 37.4x and is 2.53, above the 1.5x threshold generally considered attractive for a growth company, while FY26 consensus is -$0.56027 and FY27 is only $0.41908, making the forward multiple sensitive to any estimate cut. At $27.59, the stock is about 65.8x the FY27 consensus , underscoring how much of the valuation depends on a sharp profit inflection rather than current earnings. of -704.56x is not meaningful with negative ; of 2.50x is about 92% above the cited 1.3x healthcare average and about 14% above the 2.2x peer average, and is 19.86x. Enterprise value of approximately $7.17 billion is 1.11x the $6.44 billion market cap, reflecting the net-debt position. A third-party Fair Ratio model cited in coverage argues for a higher tailored sales multiple, but that is assumption-dependent and does not establish that current profitability or cash conversion supports a premium. Overall, the stock is expensive relative to its current earnings quality and balance-sheet risk, even though revenue growth is strong.
Balance Sheet
Cash of approximately $841 million against debt of approximately $1.546 billion leaves net debt near $705 million, or about 10.96% of market capitalization. Debt-to-equity is 477.13%, cash covers only 0.54x of debt, operating cash flow covers 0.17x of debt, and current and quick ratios of 0.93 and 0.82 indicate limited working-capital headroom. of -32.03% and of -2.21% provide no evidence of an internally generated capital cushion. Reported free cash flow of approximately $849 million produces a headline FCF yield of 13.2%, but it exceeds operating cash flow of approximately $263 million by about 3.2x; until that discrepancy is reconciled, the headline FCF and yield should not be underwritten as reliable balance-sheet support.
Growth
Revenue growth is strong at 38.2% year over year, and supplied coverage reports 2.89 million customers with average customer growth of 25.1% over two years. That supports continued demand and cross-selling potential, but earnings momentum has reversed: the two latest supplied quarters reported losses of $0.40 and $0.37 after earlier profitable quarters. The growth rate is unavailable in the bundle, and quarterly margin history is not provided, so a sustained margin-expansion trend cannot be confirmed. The September 26 AI-native weight-loss platform could improve personalization and recurring engagement, but the bundle provides no measured contribution to revenue, retention, or margins.
Business Quality
HIMS has a strong 69.53% gross margin, but operating margin of -12.75%, margin of -0.40%, profit margin of -5.51%, of -2.21%, and of -32.03% show that the current business is not yet translating gross profit into attractive returns. Current and quick ratios of 0.93 and 0.82 are both below 1.0. The company is best assessed as a consumer digital-health and telehealth platform, not as a conventional specialty-drug manufacturer, which makes customer acquisition, care delivery, retention, and regulatory execution central to its economics. Institutional ownership is 71.24% versus insider ownership of 4.95%; no ownership trend is supplied. Current business quality supports the growth opportunity, but not an unqualified premium valuation.
Capital Allocation
HIMS reports no dividend, and the bundle provides no buyback authorization or share-count history. Shares outstanding are approximately 224.94 million, but without a comparable prior share count, dilution or repurchases cannot be assessed. Capital deployment appears centered on organic platform expansion, including the AI-native weight-loss offering, but no quantified return on that investment is available. Given net debt of approximately $705 million, negative returns on equity, and unresolved cash-flow data, capital allocation has not yet demonstrated consistent shareholder-value creation.
Estimate Revisions
Revision momentum is negative across the main horizons. Current-quarter consensus of $0.05632 is unchanged over the last 7 and 30 days but is about 27% below the $0.07714 estimate 60 days ago; there were two downward revisions in 30 days and one in the last 7 days. Next-quarter consensus of $0.11466 is about 31% below its $0.165 level 90 days ago. FY26 consensus deteriorated from -$0.13 90 days ago to -$0.56027, while FY27 fell from $0.61667 to $0.41908, a decline of about 32%. There were no recommendation upgrades, downgrades, or initiations in the last 90 days, and the current recommendation mix is 2 Strong Buy, 1 Buy, and 12 Hold. Recent price-target actions were mixed and generally kept rating grades unchanged, so they do not offset the negative trend.